Comparative Anti Helicobacter Pylori Efficacy Assessment of Unani Formulation and Quintuple Regimen

• Status: Completed
• Trial end date: 2019-01-10
• Target enrollment: 0
• Participant gender: All

Summary

Helicobacter pylori (H. pylori) is a bacterium its infection is regarded the most common medical condition associated with gastritis1 more over peptic ulcer disease2, gastric adenocarcinoma3 and lymphoma.4control of H pylori infection is thought to be the solution of public health problem.5,6 rate of infection is abating in developed world 7 , but this is slow and people health is challenged, to stop or decrease the new cases is complicated despite the fact that route of transmission are still unclear .8-10 The only option for reducing incidence and prevalence is that screening of masses followed by eradication therapy. A rough estimate propose about 50% of developing country population is affected from infection than the industrialized country. Infected individual may be asymptomatic or some time present with gastroduodenal disease. Prevalence of H pylori is different in developing countries where the adult prevalence reaches up to 80% and in children it is found before the age of 10 years.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hamdard University

Criteria

Inclusion Criteria:

1. The individuals suffering from H. pylori infection .

2. Individuals having no previous history of H. pylori infection treatment.

3. Individuals living in Karachi.

4. Individuals with no pathological finding on routine examination.

5. Individuals from either socioeconomic class including lower, middle and higher.

6. Both male and female individuals between 14 to 55 years of age

7. Subjects with informed written consent

8. Patients having no complications regarding other than GIT system.

Exclusion Criteria

The following were the reason for excluding the individuals from this trial:

1. Patient with simultaneous physical illness, for example renal dialysis and uncontrolled diabetes mellitus.

2. Individuals having stomach or intestinal surgical history were excluded.

3. Individuals with past record of any herbal or allopathic medication were excluded

4. Individuals with hyper sensitivity history of drug or adverse reaction to any of the study drugs .

5. Females with pregnancy were also excluded for the safety measures

6. Individuals with coma, meningitis, and encephalitis or head injury were also excluded.

7. Hospitalized individuals due to any serious diseases were excluded.

8. Individuals with known poor compliance and history of drug abuse were excluded.